China SXT Pharmaceuticals, Inc.
SXTC
$1.05
$0.021.94%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 469.80K | 469.80K | 381.70K | 381.70K | 604.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 469.80K | 469.80K | 381.70K | 381.70K | 604.10K |
| Cost of Revenue | 325.60K | 325.60K | 213.40K | 213.40K | 559.30K |
| Gross Profit | 144.20K | 144.20K | 168.30K | 168.30K | 44.80K |
| SG&A Expenses | 4.82M | 4.82M | 2.22M | 2.22M | 620.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.14M | 5.14M | 2.44M | 2.44M | 1.18M |
| Operating Income | -4.67M | -4.67M | -2.05M | -2.05M | -575.20K |
| Income Before Tax | -4.85M | -4.85M | -2.22M | -2.22M | -747.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.85M | -4.85M | -2.22M | -2.22M | -747.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.85M | -4.85M | -2.22M | -2.22M | -747.30K |
| EBIT | -4.67M | -4.67M | -2.05M | -2.05M | -575.20K |
| EBITDA | -4.62M | -4.62M | -1.98M | -1.98M | -520.20K |
| EPS Basic | -9.67 | -9.67 | -5.14 | -5.14 | -7.30 |
| Normalized Basic EPS | -6.04 | -6.04 | -2.96 | -2.96 | -4.56 |
| EPS Diluted | -9.67 | -9.67 | -5.14 | -5.14 | -7.30 |
| Normalized Diluted EPS | -6.04 | -6.04 | -2.96 | -2.96 | -4.56 |
| Average Basic Shares Outstanding | 501.50K | 501.50K | 431.60K | 431.60K | 102.30K |
| Average Diluted Shares Outstanding | 501.50K | 501.50K | 431.60K | 431.60K | 102.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
